Preliminary effectiveness of breast cancer screening among 1.22 million Chinese females and different cancer patterns between urban and rural women
Yubei Huang(Tianjin Medical University Cancer Institute and Hospital), Kexin Chen(Harbin University of Science and Technology), Ling Leng(Tianjin University of Traditional Chinese Medicine), Lingzhi Kong, Zhenhua Yang(Huazhong University of Science and Technology), Hengmin Ma(Shandong Tumor Hospital), Yeping Zhang(Zoucheng People's Hospital), Jie Sun(Ministry of Education), Fengju Song(Tianjin Medical University Cancer Institute and Hospital), Zhenglong Lei, Yaogang Wang(Tianjin University of Traditional Chinese Medicine), Yahong Luo(Liaoning Cancer Hospital & Institute), Zhaoxiang Ye(Chinese University of Hong Kong), Hong Liu(Tianjin Anding Hospital), Jialin Wang(Shandong University), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ye Yan(Wannan Medical College), Xiong Li(Capital Medical University), Yali Cao(Third Hospital of Nanchang), Xiangjun Ma(Hainan Maternal and Child Health Hospital), Jiali Han(University of Arizona), Haixin Li(Tongji University), Xishan Hao(Tianjin Medical University Cancer Institute and Hospital), Xiuling Song(Zoucheng People's Hospital), Tie Pan(Liaoning Cancer Hospital & Institute), Sheng Zhang(Tianjin Medical University Cancer Institute and Hospital), Hong Dai(California Pacific Medical Center)
Cited by 48
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Outcome over seven years of healthy adults with and without subjective cognitive impairment
|Alzheimer s & Dementia|2010|582
Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning
|European Respiratory Journal|2019|441
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415